Research advance in tumour vaccines — shared neoantigen discovery in advanced NSCLC at ASCO 2025

Research update (NSCLC neoantigens)

Runsheng Cell reports progress in tumor vaccine R&D using whole-exome plus transcriptome profiling in a cohort of advanced non–small cell lung cancer (NSCLC) patients. Integrated bioinformatics and neoantigen prediction nominated candidate shared neoantigens that could inform off-the-shelf vaccine strategies—early-stage science, not an approved product claim.

Findings were presented at the 2025 ASCO Annual Meeting (abstract: JCO supplement link).

Refer to ASCO’s official publication for titles, authorship, and disclosures.